| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Biological Chemistry, Johns Hopkins School of Medicine, Baltimore, Maryland 21205 [A. Y. C., C. Y., L. F. L.]; Department of Radiology, New York University School of Medicine, New York, New York 10016 [M. P.]; and Research Triangle Institute, Research Triangle Park, North Carolina 27709 [M. E. W., M. C. W.]
In order to understand the high efficacy of camptothecin derivatives against human colon tumor xenografts in nude mice, we have studied the transport properties of camptothecin derivatives across cellular membranes of MDR1-overexpressing cells. MDR1 overexpression was shown to have little effect on camptothecin cytotoxicity; camptothecin was equally cytotoxic to both the drug-sensitive parental cell line, KB 3-1, and its multidrug-resistant derivative, KB V1. The ability of camptothecin to overcome MDR1-mediated resistance is most likely due to unimpaired accumulation of camptothecin in MDR1 cells as suggested from the following experiments: (a) cytotoxicity of camptothecin against KB V1 cells was not altered by the known MDR1-reversing agent, verapamil; (b) camptothecin was ineffective as compared with vinblastine in competing with [3H]azidopine for photoaffinity labeling of MDR1; (c) camptothecin was equally efficient in trapping cellular topoisomerase I molecules on chromosomal DNA in the form of cleavable complexes in both KB 3-1 and KB V1 cells.
The mechanism by which camptothecin overcomes MDR1-mediated resistance has been further studied using a number of uncharged and charged camptothecin derivatives. In contrast to the uncharged camptothecin derivatives, such as 9-amino-camptothecin and 10,11-methylenedioxy-camptothecin, the charged camptothecin derivative, topotecan, showed reduced cytotoxicity against MDR1-overexpressing KB V1 cells. The reduced cytotoxicity of topotecan in KB V1 cells was due to the overexpression of MDR1 in KB V1 cells since verapamil restored both topotecan accumulation and cytotoxicity. These results suggest that the charge on camptothecin can affect the drug's sensitivity to MDR1. The possible effect of membrane permeability in determining drug selectivity of MDR1 is discussed.
1 This work was supported by NIH Grants CA39662 (L. F. L.) and CA50529 (M. P.).
2 To whom requests for reprints should be addressed, at Department of Biological Chemistry, Johns Hopkins School of Medicine, N. Wolfe St., Baltimore, MD 21205.
Received 6/21/91. Accepted 9/11/91.
This article has been cited by other articles:
|
|
 |
|
  O. Prokopenko and O. Mirochnitchenko Ischemia-reperfusion-inducible protein modulates cell sensitivity to anticancer drugs by regulating activity of efflux transporter Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1086 - C1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Molina, S. H. Kaufmann, J. M. Reid, S. D. Rubin, M. Galvez-Peralta, R. Friedman, K. S. Flatten, K. M. Koch, T. M. Gilmer, R. J. Mullin, et al. Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data Clin. Cancer Res., December 1, 2008; 14(23): 7900 - 7908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Liao, R. W. Robey, J. Guirouilh-Barbat, K. K. W. To, O. Polgar, S. E. Bates, and Y. Pommier Reduced Expression of DNA Topoisomerase I in SF295 Human Glioblastoma Cells Selected for Resistance to Homocamptothecin and Diflomotecan Mol. Pharmacol., February 1, 2008; 73(2): 490 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. de Vries, J. Zhao, E. Kroon, T. Buckle, J. H. Beijnen, and O. van Tellingen P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan Clin. Cancer Res., November 1, 2007; 13(21): 6440 - 6449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamagata, H. Kusuhara, M. Morishita, K. Takayama, H. Benameur, and Y. Sugiyama Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients Drug Metab. Dispos., July 1, 2007; 35(7): 1142 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E.L.M. Kuppens, E. O. Witteveen, R. C. Jewell, S. A. Radema, E. M. Paul, S. G. Mangum, J. H. Beijnen, E. E. Voest, and J. H.M. Schellens A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients Clin. Cancer Res., June 1, 2007; 13(11): 3276 - 3285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhuang, C. H. Fraga, K. E. Hubbard, N. Hagedorn, J. C. Panetta, C. M. Waters, and C. F. Stewart Topotecan Central Nervous System Penetration Is Altered by a Tyrosine Kinase Inhibitor Cancer Res., December 1, 2006; 66(23): 11305 - 11313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Malavazi, M. Savoldi, S. M. Z. Di Mauro, C. F. M. Menck, S. D. Harris, M. H. d. S. Goldman, and G. H. Goldman Transcriptome Analysis of Aspergillus nidulans Exposed to Camptothecin-Induced DNA Damage. Eukaryot. Cell, October 1, 2006; 5(10): 1688 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Arakawa, H. Suzuki, S. Saito, and H. Yamada Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells. Mol. Cancer Ther., March 1, 2006; 5(3): 502 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-f. Zhou, X. Yang, Q. Wang, R. A. Coburn, and M. E. Morris EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES Drug Metab. Dispos., August 1, 2005; 33(8): 1220 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Norris, J. Smith, K. Tanabe, P. Tobin, C. Flemming, G. L. Scheffer, P. Wielinga, S. L. Cohn, W. B. London, G. M. Marshall, et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro Mol. Cancer Ther., April 1, 2005; 4(4): 547 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chatterjee, R. Digumarti, R. N. V. S. Mamidi, K. Katneni, V. V. Upreti, A. Surath, M. L. Srinivas, S. Uppalapati, S. Jiwatani, S. Subramaniam, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of an Orally Active Novel Camptothecin Analog, DRF-1042, in Refractory Cancer Patients in a Phase I Dose Escalation Study J. Clin. Pharmacol., July 1, 2004; 44(7): 723 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Garrison, L. A. Hammond, C. E. Geyer Jr., G. Schwartz, A. W. Tolcher, L. Smetzer, J. A. Figueroa, M. Ducharme, J. Coyle, C. H. Takimoto, et al. A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies Clin. Cancer Res., July 1, 2003; 9(7): 2527 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rajendra, M. K. Gounder, A. Saleem, J. H. M. Schellens, D. D. Ross, S. E. Bates, P. Sinko, and E. H. Rubin Differential Effects of the Breast Cancer Resistance Protein on the Cellular Accumulation and Cytotoxicity of 9-Aminocamptothecin and 9-Nitrocamptothecin Cancer Res., June 15, 2003; 63(12): 3228 - 3233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Rowinsky, J. Rizzo, L. Ochoa, C. H. Takimoto, B. Forouzesh, G. Schwartz, L. A. Hammond, A. Patnaik, J. Kwiatek, A. Goetz, et al. A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies J. Clin. Oncol., January 1, 2003; 21(1): 148 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Giles, J. E. Cortes, D. A. Thomas, G. Garcia-Manero, S. Faderl, S. Jeha, R. L. De Jager, and H. M. Kantarjian Phase I and Pharmacokinetic Study of DX-8951f (Exatecan Mesylate), a Hexacyclic Camptothecin, on a Daily-Times-Five Schedule in Patients with Advanced Leukemia Clin. Cancer Res., July 1, 2002; 8(7): 2134 - 2141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gore, W. ten Bokkel Huinink, J. Carmichael, A. Gordon, N. Davidson, R. Coleman, M. Spaczynski, J.-F. Heron, G. Bolis, H. Malmstrom, et al. Clinical Evidence for Topotecan-Paclitaxel Non-Cross-Resistance in Ovarian Cancer J. Clin. Oncol., April 1, 2001; 19(7): 1893 - 1900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Erlichman, S. A. Boerner, C. G. Hallgren, R. Spieker, X.-Y. Wang, C. D. James, G. L. Scheffer, M. Maliepaard, D. D. Ross, K. C. Bible, et al. The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux Cancer Res., January 1, 2001; 61(2): 739 - 748. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. W. Jonker, J. W. Smit, R. F. Brinkhuis, M. Maliepaard, J. H. Beijnen, J. H. M. Schellens, and A. H. Schinkel Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan J Natl Cancer Inst, October 18, 2000; 92(20): 1651 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rowinsky, T. R. Johnson, C. E. Geyer Jr, L. A. Hammond, S. G. Eckhardt, R. Drengler, L. Smetzer, J. Coyle, J. Rizzo, G. Schwartz, et al. DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies J. Clin. Oncol., September 17, 2000; 18(17): 3151 - 3163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lesueur-Ginot, D. Demarquay, R. Kiss, P. G. Kasprzyk, L. Dassonneville, C. Bailly, J. Camara, O. Lavergne, and D. C. H. Bigg Homocamptothecin, an E-Ring Modified Camptothecin with Enhanced Lactone Stability, Retains Topoisomerase I-targeted Activity andAntitumor Properties Cancer Res., June 1, 1999; 59(12): 2939 - 2943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Relias and J. Andrew Skirvin Review : Topoisomerase I inhibitors: 1. Topotecan Journal of Oncology Pharmacy Practice, December 1, 1997; 3(4): 173 - 185. [Abstract] [PDF]
|
|
|
|
 |
|
 R. J. D. Reid, E. A. Kauh, and M.-A. Bjornsti Camptothecin Sensitivity Is Mediated by the Pleiotropic Drug Resistance Network in Yeast J. Biol. Chem., May 2, 1997; 272(18): 12091 - 12099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Kaufmann, P. A. Svingen, S. D. Gore, D. K. Armstrong, Y.-C. Cheng, and E. K. Rowinsky Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells Blood, March 15, 1997; 89(6): 2098 - 2104. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
